- Integration
- The FDA summary describes DICOM 3.0 input streamed from a compatible MRI machine through a designated DICOM destination, router, and processor, with denoised output routed to a PACS or other DICOM destination; validate the exact local path and failure handling.
FDA source Exact FDA submission Checked 2026-09-04
The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary.
- Deployment and data flow
- Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
- Security and privacy
- Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
- Training and support
- Only qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
- Monitoring and change control
- Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Processing time depends on CPU, input size, and image count; queued jobs are processed sequentially. The FDA summary does not establish universal noise-reduction benefit, diagnostic sensitivity, specificity, or clinical outcomes.
FDA source Exact FDA submission Checked 2026-09-04
Release and scope verification
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K241121 before acceptance. Later family features are not evidence for this exact submission.
exact submission · checked 2026-09-04 Interoperability acceptance
The FDA summary describes DICOM 3.0 input streamed from a compatible MRI machine through a designated DICOM destination, router, and processor, with denoised output routed to a PACS or other DICOM destination; validate the exact local path and failure handling. Test representative identifiers, geometry, measurements, units, routing, failure handling, and round trips locally.
exact submission · checked 2026-09-04 Deployment and security qualification
The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.
exact submission · checked 2026-09-04 Clinical acceptance
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Processing time depends on CPU, input size, and image count; queued jobs are processed sequentially. The FDA summary does not establish universal noise-reduction benefit, diagnostic sensitivity, specificity, or clinical outcomes.
exact submission · checked 2026-09-04 Define stop-use, escalation, rollback, and revalidation triggers before production use.
Economic evaluation
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.
product family · checked 2026-09-04 Lifecycle monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Processing time depends on CPU, input size, and image count; queued jobs are processed sequentially. The FDA summary does not establish universal noise-reduction benefit, diagnostic sensitivity, specificity, or clinical outcomes.
exact submission · checked 2026-09-04 Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.